In preparing for the July 2010 meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, the FDA sought to provide the committee members with all available data relevant to the cardiovascular safety of rosiglitazone.

FORBES: The FDA Responds To Steve Nissen's Criticism Of Upcoming Avandia Meeting